Sirona Announces Shares for Services Agreement

Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the
"Company") is pleased to announce that it has entered into a business consulting
agreement (the "Agreement") with PRC Partners Ltd. of Hong Kong ("PRC"), for a
six month term commencing July 15, 2014. 


As compensation for the services to be provided, PRC will receive a total of
1,500,000 common shares of the Company, in tranches of 250,000 common shares
each, on a monthly basis starting August 15, 2014. PRC will also receive stock
options in the Company, under the Company's stock option plan, entitling it to
purchase 500,000 common shares at a price of $0.15 per share and 500,000 common
shares at a price of $0.20 per share expiring 60 days after the Agreement is
terminated. 


Services to be provided by PRC include consultation, advice, and the arrangement
of strategic relationships with other companies and the acquisition of projects,
access to capital markets in Europe, and similar activities designed to further
the business and development of the Company.


The Agreement and all securities proposed to be issued thereunder are subject to
the acceptance of the TSX Venture Exchange.


About PRC Partners

PRC Partners is a Hong Kong-based corporate development consulting firm owned
Frank Haentjes. Mr. Haentjes is a native of Cologne, Germany, raised and
educated in Brazil, Germany and the United States. He has been living and
working in China for much of the last decade, successfully assisting Canadian
public companies in tapping investment funds from State-owned Enterprises and
high-net-worth individuals. 


PRC Partners has a self-professed focus on the discovery of undervalued and
promising growth companies, and serves these companies by increasing visibility
and accessing capital through an experienced network of investors. 


Due to the increasing demand from his investors, Mr. Haentjes has taken a strong
interest in technology as well as in biotech/healthcare deals that are either
public or about to go public. He has extensive relationships in Asia, Europe and
the Middle East. He will be providing the services on behalf of PRC Partners.


About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a
proprietary technology platform developed at its laboratory facility in France.
The company specializes in the stabilization of carbohydrate molecules, with the
goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are
patented as new chemical entities for maximum commercial protection and revenue
potential. Newly developed compounds are licensed to leading companies around
the world in return for licensing and milestone fees and ongoing royalty
payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient
of multiple French national scientific awards and a European Union and French
government grant. For more information visit www.sironabiochem.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. 


Sirona Biochem cautions you that statements included in this press release that
are not a description of historical facts may be forward-looking statements.
Forward-looking statements are only predictions based upon current expectations
and involve known and unknown risks and uncertainties. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of release of the relevant information, unless explicitly stated
otherwise. Actual results, performance or achievement could differ materially
from those expressed in, or implied by, Sirona Biochem's forward-looking
statements due to the risks and uncertainties inherent in Sirona Biochem's
business including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in development, testing,
obtaining regulatory approval, producing and marketing its products; unexpected
adverse side effects or inadequate therapeutic efficacy of its products that
could delay or prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from other
pharmaceutical or biotechnology companies; and its ability to obtain additional
financing to support its operations. Sirona Biochem does not assume any
obligation to update any forward-looking statements except as required by law.



FOR FURTHER INFORMATION PLEASE CONTACT: 

For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp. 
Phone: [phone]
Email: [e-mail]